Business Wire

ABB Robotics to Develop Solutions for the Hospital of the Future

Share

ABB announced that it will introduce collaborative robots to medical laboratories as it opens a new healthcare hub at the Texas Medical Center (TMC) innovation campus in Houston, Texas.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190709005953/en/

Advanced collaborative robotics for medical laboratories and hospitals (Photo: Business Wire)

Advanced collaborative robotics for medical laboratories and hospitals (Photo: Business Wire)

The facility will be ABB’s first dedicated healthcare research center when it opens in October 2019. ABB’s research team will work on the TMC campus with medical staff, scientists and engineers to develop non-surgical medical robotics systems, including logistics and next-generation automated laboratory technologies.

Sami Atiya, President of ABB’s Robotics and Discrete Automation business said, “The next-generation laboratory processes developed in Houston will speed manual medical laboratory processes, reducing and eliminating bottlenecks in laboratory work and enhancing safety and consistency. This is especially applicable for new high-tech treatments, such as the cancer therapies pioneered at the Texas Medical Center, which today require manual and time-consuming test processes.”

Today, a limiting factor to the number of patients who can be treated is the need for highly skilled medical experts who spend a large part of their day doing repetitive and low value tasks, such as preparing slides and loading centrifuges. Using robots to automate these tasks will enable medical professionals to focus on more highly skilled and productive work, while ultimately helping more people to receive treatment through dramatically speeding the testing process.

ABB has analyzed a wide range of current manual medical laboratory processes and estimates that 50% more tests could be carried out every year using automation, while training robots to undertake repetitive processes will reduce the need for people to do tasks which cause repetitive strain injury (RSI).

As the world population ages, countries are spending an increasingly larger proportion of their GDP on healthcare. In addition to improving the quality of patient care, increasing healthcare efficiency through automation can ease some of the societal, political and financial challenges that this will cause. The market for non-surgical medical robots is estimated to reach nearly 60,000 by 2025 with the market almost quadrupling vs. 2018, according to an internal ABB research.

ABB’s collaborative robots, which already operate in food and beverage laboratories worldwide, are well suited to medical facilities as they don’t require safety fences to operate safely and efficiently alongside people. The robots will undertake a range of repetitive, delicate and time-consuming activities including dosing, mixing and pipetting tasks as well as sterile instrument kitting and centrifuge loading and unloading.

Houston is a focal point for medical technology research globally and the TMC innovation ecosystem is the ideal location for ABB’s new healthcare hub. A 20-strong team from ABB Robotics will work in the new 5,300 sq ft (500m2) research facility, which includes an automation laboratory and robot training facilities, as well as meeting spaces for co-developing solutions with innovation partners.

“With this exciting partnership, Texas Medical Center continues to push the boundaries of innovative collaboration with cutting-edge industry partners by establishing TMC as the epicenter for ABB Robotics’ entry into the healthcare space,” said Bill McKeon, President & CEO of Texas Medical Center. “Operating a city within a city that sees 10 million patients on an annual basis, it is essential to prioritize efficiency, and precision and to develop processes that are easily repeatable in nature. By bringing ABB into the fold at TMC Innovation with this first-of-its-kind R&D facility for creating robotics solutions in healthcare, TMC is emphasizing its commitment to doing just that.”

“We are proud to co-develop collaborative robotics systems for the Hospital of the Future with one of the world’s most advanced partners and to test them in real-world laboratories to ensure they add value to healthcare professionals, driving innovation and transforming how medical laboratories operate worldwide,” added Atiya. “A key element of ABB’s long-term growth strategy is to continue to invest and innovate in service robotics, bringing our automation expertise to new areas such as healthcare and building on our automotive and electronics sectors business.”

ABB (ABBN: SIX Swiss Ex) is a pioneering technology leader with a comprehensive offering for digital industries. With a history of innovation spanning more than 130 years, ABB is today a leader in digital industries with four customer-focused, globally leading businesses: Electrification, Industrial Automation, Motion, and Robotics & Discrete Automation, supported by its common ABB Ability™ digital platform. ABB’s market‑leading Power Grids business will be divested to Hitachi in 2020. ABB operates in more than 100 countries with about 147,000 employees.

ABB Robotics is a pioneer in industrial and collaborative robots and advanced digital services. As one of the world’s leading robotics suppliers, we are active in 53 countries and over 100 locations and have shipped over 400,000 robot solutions for a diverse range of industries and applications. We help our customers to improve flexibility, efficiency, safety and reliability, while moving towards the connected and collaborative factory of the future. www.abb.com/robotics

About TMC INNOVATION: Texas Medical Center (TMC)—the largest medical city in the world—is at the forefront of advancing life sciences. Home to the brightest minds in medicine, TMC nurtures cross-institutional collaboration, creativity, and innovation among its 106,000-plus employees. With a campus of more than 50 million square feet, TMC annually hosts 10 million patients, performs over 180,000 surgeries, conducts over 750,000 ER visits, performs close to 14,000 heart surgeries, and delivers over 25,000 babies. Beyond patient care, TMC is pushing the boundaries of clinical research across its extensive network of partner institutions on a daily basis, pioneering effective health policy solutions to address the complex health care issues of today, and cultivating cutting-edge digital health applications and medical devices. For more information, please visit www.tmc.edu.

Contact information

ABB Ltd
Affolternstrasse 44
8050 Zurich
Switzerland

Media Relations
Phone: +41 43 317 71 11
Email: media.relations@ch.abb.com

Investor Relations
Phone: +41 43 317 71 11
Email: investor.relations@ch.abb.com

TMC Media Contacts:
Public Content
+1 713 524 2800
Mark Sullivan / Jonathan Babin
mark@public-content.com / jonathan@public-content.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines13.11.2019 11:29:00 CETPress release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that NHS Wales has accepted an offer for all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England. This means that once the contract is finalized, patients with CF in Wales ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can access ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations can access SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor in the coming weeks. The agreement also offers expanded access to KALYDECO ® (ivacaftor) to include those patients ages 12 months and older who have one of the nine licensed gating mutations. “Today’s a

Software Testing and Digital Transformation Partners Recognized at 2019 Tricentis Partner Awards13.11.2019 11:00:00 CETPress release

Tricentis, the cloud’s #1 Continuous Testing Platform, today recognized top-performing partners from around the world during Tricentis Accelerate 2019 in Vienna, Austria. In its 5th year, the Tricentis Partner Awards recognize organizations for accelerating digital transformation across the enterprise. Award winners were selected from more than 300 different partners worldwide based on their collaboration with Tricentis, customers, and their advocacy for Tricentis’ automation methodologies. “Tricentis partners are leading the way for organizations to innovate faster, reduce business risk, and optimize cost,” said Alan Ota, Senior Vice President of Strategic Alliances, Tricentis. “Our partners are instrumental to our business and are focused on delivering the best in-class testing solutions to our joint customers. Our tremendous growth would not be possible without our global partners. We’re proud to acknowledge the achievements made by our partners in 2019 and look forward to continuin

Applicaster Appoints Jason Johns as Vice President of Sales, EMEA and APAC13.11.2019 10:00:00 CETPress release

Applicaster, the company simplifying the lifecycle management of direct-to-consumer media applications, today announced the appointment of Jason Johns as Vice President of Sales, EMEA and APAC. In his role, Johns will oversee Applicaster’s EMEA and APAC commercial and go-to-market strategies. “There is an incredible amount of opportunity in the media app market,” said Johns. “Because of our ability to enable frictionless growth for customers, we’re very well positioned to take advantage of this opportunity. Beyond the market opportunity, I was attracted to Applicaster because of the company’s customer-first culture plus its ability and desire to drive value lead engagements. Few businesses buy technology without a clear understanding of the business case and full transparency of the cost-of-ownership around their technology investments - Applicaster understands this and provides flexible commercial models that scale and can easily be upgraded and expanded as business requirements evolv

Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy13.11.2019 09:00:00 CETPress release

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Rucaparib will soon be available as an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.3 Rucaparib is indicated for eligible patients regardless of BRCA status, which means it can be prescribed for women who harbor a BRCA mutation or who are BRCA wild-type.3 “We very much welcome the arrival of the PARP inhibitor rucaparib, which offers a new treatment option after surgery and two lines of chemotherapy to all eligible women affected by relapsed ovarian cancer,” declared Nicoletta Cerana, National President of Acto Onlus, the number one Italian network of patient associations involved in the fight against ovarian cancer and gynecological tumors. “Ovarian cancer is a highly lethal

Traxens Presents Solutions for Port Industry at Smart Ports Barcelona13.11.2019 07:30:00 CETPress release

Traxens, a company providing high-value data and services for the supply chain industry, announces today that it will present its smart asset tracking solutions at the Smart Ports Barcelona event, Smart Ports, Piers of the Future, November 19 to 21. Its tailored Industrial Internet of Things (IIoT) solutions are specifically designed to meet the needs of the port industry by providing near real-time insight into the end-to-end global supply chain. Traxens’ solution provides comprehensive, precise and timely data on cargo, through tracking logistic assets in transit anywhere in the world. Traxens’ patented breakthrough Internet of Things (IoT) technology brings improved efficiency and security, greater transparency and enhanced asset utilization whilst opening up new opportunities for all actors involved in the global supply chain. With Traxens’ solutions, ports can improve their efficiency and the interoperability of the systems with a trusted third party. For example, the Cargo Commun

PMC Group Announces Agreement to Acquire Lanxess’ Organotin Specialties Business13.11.2019 06:30:00 CETPress release

PMC Group N.A., Inc. ("PMC") and Lanxess Organometallics GmbH are pleased to announce that the parties have reached an agreement whereby PMC’s European subsidiary will acquire the organotin specialties product line (the “Business”) from Lanxess. The transaction is scheduled to close by year end, subject to customary closing conditions. The Business includes Lanxess’ global organotin catalyst, organotin specialties and intermediates product lines. The transaction includes a toll manufacturing agreement under which Lanxess will continue to manufacture certain products post-closing for PMC at its Bergkamen, Germany organometallics manufacturing facility. Mr. Debtosh Chakrabarti, President of PMC said, “This acquisition represents PMC’s continuing commitment to the organotin industry and is synergistic to our existing organometallics and catalyst businesses. We believe that the customer base of the Business as well as all of PMC’s customers will benefit significantly from combining the tec